Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) bought by American Century Companies Inc.

American Century Companies Inc. increased its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 14.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 125,169 shares of the company’s stock after buying an additional 15,911 shares during the period. American Century Companies Inc. owned approximately 0.15% of Atea Pharmaceuticals worth $414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Sunpointe LLC purchased a new position in shares of Atea Pharmaceuticals in the 4th quarter valued at about $36,000. China Universal Asset Management Co. Ltd. boosted its stake in Atea Pharmaceuticals by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 16,179 shares of the company’s stock valued at $65,000 after purchasing an additional 6,526 shares in the last quarter. Tidal Investments LLC purchased a new position in shares of Atea Pharmaceuticals in the first quarter worth $87,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Atea Pharmaceuticals in the 1st quarter worth $123,000. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of Atea Pharmaceuticals by 238.8% in the first quarter. Public Employees Retirement System of Ohio now owns 61,033 shares of the company’s stock valued at $247,000 after buying an additional 43,021 shares during the last quarter. 86.67% of the shares are currently held by hedge funds and other institutional investors.

Indoor activity

In related news, CEO Jean-Pierre Sommadossi sold 33,941 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $4.05, for a total transaction of $137,461.05. Following the sale, the chief executive officer now directly owns 5,890,053 shares of the company’s stock, valued at $23,854,714.65. The transaction was disclosed in a filing with the SEC, which can be accessed via this hyperlink. Insiders own 17.80% of the company’s shares.

Analyst upgrades and downgrades

A number of equities analysts recently issued reports on AVIR shares. William Blair upgraded Atea Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Morgan Stanley upgraded Atea Pharmaceuticals from an “underweight” rating to an “equal weight” rating and upped their price objective for the stock from $2.00 to $6.88 in a research note on Tuesday , August 13.

Read our latest report on Atea Pharmaceuticals

Atea Pharmaceuticals trading down 1.2%

Shares of NASDAQ AVIR opened at $3.33 on Friday. The stock has a market cap of $280.46 million, a price-to-earnings ratio of -1.70 and a beta of 0.17. Atea Pharmaceuticals, Inc. it has a 12-month low of $2.77 and a 12-month high of $4.60. The company has a 50 day simple moving average of $3.65 and a two hundred day simple moving average of $3.69.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report ) last issued its earnings results on Wednesday, August 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.28. In the same quarter last year, the company earned ($0.34) EPS. Analysts predict that Atea Pharmaceuticals, Inc. will record -2.21 EPS for the current year.

Profile Atea Pharmaceuticals

(Free Report)

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops and commercializes antiviral therapies for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in the phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.

Further reading

Receive daily news and reviews for Atea Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Atea Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.